Headlands Technologies LLC Increases Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Headlands Technologies LLC increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMCFree Report) by 34.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,911 shares of the biotechnology company’s stock after purchasing an additional 489 shares during the period. Headlands Technologies LLC’s holdings in Blueprint Medicines were worth $96,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Pinebridge Investments L.P. acquired a new position in Blueprint Medicines in the 2nd quarter valued at $46,000. Cutler Group LLC CA raised its holdings in Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 944 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Blueprint Medicines in the 4th quarter valued at $57,000. Dark Forest Capital Management LP acquired a new position in Blueprint Medicines in the 1st quarter valued at $63,000. Finally, Steward Partners Investment Advisory LLC raised its holdings in Blueprint Medicines by 24.9% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 1,682 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 335 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $76.54 on Monday. The company has a fifty day moving average price of $82.75 and a 200 day moving average price of $64.16. The company has a quick ratio of 4.01, a current ratio of 4.09 and a debt-to-equity ratio of 1.03. Blueprint Medicines Co. has a twelve month low of $37.82 and a twelve month high of $94.00.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Christopher K. Murray sold 600 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $71.43, for a total value of $42,858.00. Following the completion of the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at approximately $1,749,677.85. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Blueprint Medicines news, insider Christopher K. Murray sold 600 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $71.43, for a total value of $42,858.00. Following the completion of the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at approximately $1,749,677.85. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christopher K. Murray sold 5,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at $1,837,125. The disclosure for this sale can be found here. Insiders sold a total of 51,314 shares of company stock valued at $3,895,268 in the last ninety days. Insiders own 3.88% of the company’s stock.

Analysts Set New Price Targets

BPMC has been the subject of several analyst reports. Oppenheimer upgraded Blueprint Medicines from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a report on Friday, October 27th. Raymond James upped their price objective on Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a report on Friday, December 22nd. Morgan Stanley upped their price objective on Blueprint Medicines from $59.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. Needham & Company LLC upped their price objective on Blueprint Medicines from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, October 27th. Finally, Wells Fargo & Company upped their price objective on Blueprint Medicines from $86.00 to $115.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Three analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.00.

Read Our Latest Stock Report on Blueprint Medicines

Blueprint Medicines Profile

(Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib.

Further Reading

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.